Literature DB >> 35747314

New agents for DOAC reversal: a practical management review.

Katie White1, Uzma Faruqi2, Alexander Ander T Cohen3.   

Abstract

Bleeding is the commonest and most concerning adverse event associated with anticoagulants. Bleeding, depending on the severity, is managed in various ways, and for severe or life-threatening bleeding, specific antidotes are indicated and recommended. This review provides guidance relating to specific direct oral anticoagulant (DOAC) reversal agents, the antidotes. We discuss their indications for use, dosing, and potential side effects.
Copyright © 2022 Medinews (Cardiology) Limited.

Entities:  

Keywords:  DOAC antidotes; DOAC reversal; anticoagulation; bleeding risk; direct oral anticoagulant (DOAC)

Year:  2022        PMID： 35747314      PMCID： PMC9196076          DOI： 10.5837/bjc.2022.001

Source DB:  PubMed          Journal:  Br J Cardiol        ISSN： 0969-6113


  20 in total

1.  Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Authors:  Jan Beyer-Westendorf; Kati Förster; Sven Pannach; Franziska Ebertz; Vera Gelbricht; Christoph Thieme; Franziska Michalski; Christina Köhler; Sebastian Werth; Kurtulus Sahin; Luise Tittl; Ulrike Hänsel; Norbert Weiss
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.

Authors:  Charles V Pollack; Paul A Reilly; Joanne van Ryn; John W Eikelboom; Stephan Glund; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Chak-Wah Kam; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Gordon Royle; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Peter Verhamme; Bushi Wang; Laura Young; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2017-07-11       Impact factor: 91.245

Review 3.  Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.

Authors:  C Chai-Adisaksopha; C Hillis; T Isayama; W Lim; A Iorio; M Crowther
Journal:  J Thromb Haemost       Date:  2015-10-05       Impact factor: 5.824

4.  Haematological management of major bleeding associated with direct oral anticoagulants - UK experience.

Authors:  Laura Green; Joachim Tan; Sotiris Antoniou; Raza Alikhan; Nicola Curry; Tamara Everington; Khalid Saja; Simon Stanworth; Campbell Tait; Joan K Morris; Peter MacCallum
Journal:  Br J Haematol       Date:  2019-02-19       Impact factor: 6.998

5.  Trends in the prescription of novel oral anticoagulants in UK primary care.

Authors:  Simone Y Loo; Sophie Dell'Aniello; Laetitia Huiart; Christel Renoux
Journal:  Br J Clin Pharmacol       Date:  2017-05-04       Impact factor: 4.335

6.  Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.

Authors:  Claes Held; Elaine M Hylek; John H Alexander; Michael Hanna; Renato D Lopes; Daniel M Wojdyla; Laine Thomas; Hussein Al-Khalidi; Marco Alings; Dennis Xavier; Jack Ansell; Shinya Goto; Witold Ruzyllo; Mårten Rosenqvist; Freek W A Verheugt; Jun Zhu; Christopher B Granger; Lars Wallentin
Journal:  Eur Heart J       Date:  2014-12-12       Impact factor: 29.983

7.  Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.

Authors:  Robert P Giugliano; Christian T Ruff; Stephen D Wiviott; Francesco Nordio; Sabina A Murphy; Johannes A N Kappelhof; Minggao Shi; Michele F Mercuri; Elliott M Antman; Eugene Braunwald
Journal:  Am J Med       Date:  2016-03-17       Impact factor: 4.965

8.  Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.

Authors:  Ravi Sarode; Truman J Milling; Majed A Refaai; Antoinette Mangione; Astrid Schneider; Billie L Durn; Joshua N Goldstein
Journal:  Circulation       Date:  2013-08-09       Impact factor: 29.690

9.  Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.

Authors:  Lori-Ann Linkins; Peter T Choi; James D Douketis
Journal:  Ann Intern Med       Date:  2003-12-02       Impact factor: 25.391

10.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Authors:  Deborah M Siegal; John T Curnutte; Stuart J Connolly; Genmin Lu; Pamela B Conley; Brian L Wiens; Vandana S Mathur; Janice Castillo; Michele D Bronson; Janet M Leeds; Florie A Mar; Alex Gold; Mark A Crowther
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245
View more
  1 in total

Review 1.  Proximal femur fractures in patients taking anti-coagulants: has anything changed?

Authors:  Marilena Giannoudi; Peter V Giannoudis
Journal:  EFORT Open Rev       Date:  2022-05-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.